Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Solid Tumor 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × prexasertib × Other solid neoplasm × Clear all
NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
29 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡